Tustin-based Radient Pharmaceuticals Corp. said it is buying Provista Diagnostics Inc. of Phoenix.
Terms of the deal weren’t disclosed.
Radient, a publicly traded company with annual revenue of about $20 million, makes drugs and sells cancer diagnostic tests. Much of its operations are in China.
Provista sells blood tests for cancer, Alzheimer’s disease and dementia.
Radient is buying Provista in order to build a “more identifiable, broader and more profitable” diagnostic testing business, said Douglas MacLellan, its chief executive, in a release.
The company was once known as AMDL Inc., but it changed its name last year as an umbrella for its lines of business.
